Ligand id: 4594

Name: dapagliflozin

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: dapagliflozin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 99.38
Molecular weight 408.13
XLogP 2.94
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Approved to treat diabetes mellitus, type 2.
The fixed-dose drug Xigduo XR® contains dapagliflozin (as dapagliflozin propanediol monohydrate PubChem CID 56841155) and metformin hydrochloride.
Mechanism Of Action and Pharmacodynamic Effects
Dapagliflozin inhibits sodium-glucose transport protein subtype 2 (SGLT2), which accounts for >90% of glucose reabsorption from the kidneys. Inhibition of this transporter leads to excretion of blood glucose into urine. Dapagliflozin is >1000 times more inhibitory at SGLT2 than SGLT1, meaning that its effects on intestinal glucose absorption are negligible. Although this drug could be equally effective in treating type 1 diabetes, its approval restricts use to type 2 disease.
External links